Physician profile
Samireh Said
NPI 1336129998
$21,113.26
in general payments reported to CMS, 2019-2025
12 companies · $3,108 in 2025
The $3,108 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,391 · 2020: $5,427 · 2021: $2,000 · 2022: $158 · 2023: $2,971 · 2024: $58.80 · 2025: $3,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,830 · Food and Beverage: $2,587 · Consulting Fee: $625 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,830.48 |
| Food and Beverage | $2,586.61 |
| Consulting Fee | $625.00 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,832.97 | 2019-2022 | |
| Merz North America, INC. | $4,839.96 | 2019-2025 | Xeomin |
| Pierre Fabre Pharmaceuticals, INC. | $2,000.00 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $991.08 | 2020-2023 | Jublia, Arazlo, Duobrii |
| Abbvie INC. | $811.94 | 2022-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $342.68 | 2023 | |
| Revance Therapeutics, INC. | $141.25 | 2024-2025 | Daxxify |
| Incyte Corporation | $94.99 | 2023 | |
| Galderma Laboratories, L.P. | $23.02 | 2022 | |
| Dermavant Sciences, INC. | $13.31 | 2024 | Vtama |
| Allergan, INC. | $12.22 | 2022 | |
| Organon LLC | $9.84 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samireh Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.